Vitamin C supplementation of myeloma patients undergoing stem cell transplantation

INTERVENTION: Vitamin C tablets: 1g twice daily for 5 weeks Commencing one week prior to HSCT Adherence monitored by tablet return and plasma levels CONDITION: Cancer ‐ Myeloma Myeloma; ; Myeloma PRIMARY OUTCOME: To determine the proportion of participants who achieve and maintain adequate levels of vitamin C, defined as a minimum level of 50 µmol/L plasma vitamin C. [Weekly assessments over 5 weeks (and after 2 week washout for a subset of patients)] SECONDARY OUTCOME: To assess biomarkers of inflammation (exploratory, e.g. CRP, procalcitonin, cell counts and differentials).[weekly assessments over 5 weeks (and after 2 week washout for a subset of patients).] To assess health‐related quality of life using the EORTC QLQ C30 form [weekly assessments over 5 weeks] To assess the composite of incidence and severity of infectious episodes (febrile neutropenia), as assessed by presence of fever (thermometer >38 degrees Celsius) and plasma C‐reactive protein levels (>50 mg/L).[Weekly assessments carried out over 5 weeks] To assess the composite of incidence and severity of oral mucositis using the WHO oral toxicity scale [weekly assessments over 5 weeks] INCLUSION CRITERIA: 1. Myeloma patient scheduled for HSCT 2. Aged 18 years and over